The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. However, sofosbuvir plus ribavirin therapy is associated with relapse in 15% to 30% of patients with HCV GT-1. Neither the mechanism of relapse nor the optimal re-treatment strategy for these patients is defined.
C hronic hepatitis C virus (HCV) infection is a major cause of chronic liver disease and hepatocellular carcinoma and the leading indication for liver transplantation in Western countries (1, 2) . Until recently, HCV treatment consisted of combination therapy with pegylated interferon (IFN) and ribavirin, with the addition of an HCV protease inhibitor (boceprevir or telaprevir) in recent years. In 2013, the U.S. Food and Drug Administration approved sofosbuvir plus ribavirin as the first IFN-free treatment of HCV genotype 2 or 3 and for patients with genotype 1 (GT-1) who are IFN-ineligible (3) (4) (5) (6) (7) . Although sofosbuvir (an NS5B inhibitor) plus ribavirin is welltolerated and effective with sustained virologic response (SVR) rates from 68% to 76% in patients with HCV GT-1 (8, 9) , modest rates of relapse in patients with advanced liver disease and transplant recipients have been seen (8, 10, 11) . Recent studies using sofosbuvir combined with ledipasvir (an NS5A inhibitor) for 12 weeks demonstrated high SVR rates (95% to 99%) in treatment-naive patients with HCV GT-1 (12) (13) (14) (15) . Ledipasvir has potent antiviral activity against the S282T resistance-associated variant, known to reduce susceptibility to sofosbuvir in vitro (16) .
As previously reported, 17 of 54 patients treated with sofosbuvir plus ribavirin for 24 weeks in the National Institute of Allergy and Infectious Diseases (NIAID) SPARE study had relapse after treatment (8) . We hypothesized that the combination of a second potent direct-acting antiviral agent (DAA) with sofosbuvir could result in SVR, even in patients with relapse after sofosbuvir plus ribavirin therapy and who may harbor the S282T mutation. To test this hypothesis, we re-treated those patients with sofosbuvir plus ledipasvir for 12 weeks.
METHODS

Design Overview
All patients who had relapse after 24 weeks of treatment with sofosbuvir plus ribavirin in the NIAID SPARE study (8) were offered re-treatment with sofosbuvir plus ledipasvir in the ongoing, phase 2a, open-label NIAID See also:
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Original Research SYNERGY study (ClinicalTrials.gov: NCT01805882). Of the 17 eligible patients, 3 did not participate in the study. Fourteen patients enrolled and were treated with 400 mg of sofosbuvir and 90 mg of ledipasvir, administered daily as a single combination tablet, for 12 weeks.
Setting and Patients
The trial was conducted at the National Institutes of Health (NIH) in Bethesda, Maryland, and at community clinics that are part of the District of Columbia Partnership for HIV/AIDS Progress in Washington, DC. Written informed consent, which was approved by the NIAID Institutional Review Board, was obtained from all study patients. Eligibility criteria included documented HCV GT-1 infection and relapse in the NIAID SPARE study (8) . Liver fibrosis stage was determined by biopsy within 3 years of enrollment in the NIAID SPARE study.
The study was approved by the NIAID Institutional Review Board. It was conducted in adherence to the Good Clinical Practice guidelines and with regulatory requirements consistent with the Declaration of Helsinki.
Outcomes and Follow-up Efficacy Assessments
Plasma HCV RNA levels were measured using the Abbott RealTime HCV assay, with a lower limit of quantification of 12 IU/mL and a lower limit of detection of 3 IU/mL, or the Roche Cobas TaqMan HCV assay, version 2.0, with a lower limit of quantification of 43 IU/mL and a lower limit of detection of 15 IU/mL.
Safety Assessments
Patients were closely monitored for adverse events. Clinical laboratory results were assessed while receiving therapy (4, 8, and 12 weeks) and afterward (2, 4, 8 , and 12 weeks after treatment). Adverse events were graded from 1 (mild) to 4 (severe), according to the NIAID Division of AIDS Toxicity Table (version 1.0).
Interleukin-28B Genotyping
Interleukin-28B genotype (rs12979860) was determined as previously described (8) .
Clinical End Points
The primary end point was the proportion of patients with unquantifiable plasma HCV viral load 12 weeks after treatment completion. Safety end points included frequency and severity of adverse events, discontinuations due to adverse events, and safety laboratory changes.
Statistical Analysis
Primary safety and efficacy data were analyzed by intention-to-treat (all patients who initiated study medication). Missing virologic data were imputed if data from preceding and succeeding time points were obtained. Baseline demographics were described using frequency statistics. Comparisons were calculated using either nonparametric tests or t tests with GraphPad Prism, version 6.0 (GraphPad Software).
Role of the Funding Source
This study was funded in part by the National Cancer Institute, the intramural programs of the NIH Clinical Center and NIAID, and a Collaborative Research and Development Agreement between the NIH and Gilead Sciences. The study sponsor was the Regulatory Compliance and Human Participants Protection Branch of the NIAID. The sponsor reviewed the study and provided oversight. However, it did not play a role in designing the study; collecting, analyzing, or interpreting the data; or the preparation, review, approval, or submission of the manuscript for publication. All study medications were provided by Gilead Sciences, which did not have a role in the design or conduct of the study, writing of the manuscript, or the decision to submit the manuscript for publication.
RESULTS
Baseline Characteristics of Patients
Most study patients were black men with an unfavorable interleukin-28B non-CC genotype ( Table 1) . There was a high representation of patients with HCV GT-1a infection, increased baseline HCV viral load (Ͼ800 000 IU/mL), increased body mass index (Ͼ30 kg/m 2 ), and advanced liver disease (Knodell Histology Activity Index score of 3 or 4) (17).
Presence of S282T Mutation
At the time of relapse after sofosbuvir plus ribavirin treatment in the SPARE trial, 13 of 14 patients had wildtype virus by population sequencing (Supplement, available at www.annals.org). The 1 exception achieved un-
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The treatment of hepatitis C virus is changing rapidly with the introduction of interferon-free regimens that include direct-acting antiviral drugs, such as sofosbuvir. Although treatment generally results in sustained viral response, some patients have relapse after initial treatment.
Contribution
In a small, nonrandomized study, 14 patients who had relapse after treatment with sofosbuvir plus ribavirin were re-treated with sofosbuvir plus ledipasvir for 12 weeks. All patients, including those with advanced liver disease, achieved a sustained virologic response. The combination was generally well-tolerated.
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Re-treatment of Chronic HCV Genotype 1 Infection After Relapse quantifiable HCV RNA levels by week 2 of therapy in SPARE and the virus remained undetectable through the end of treatment. He missed his visit at 26 weeks (2 weeks after treatment), but at 28 weeks (4 weeks after treatment), his HCV viral load was 374 IU/mL and the S282T mutation was readily detected by population sequencing. By 36 weeks (12 weeks after treatment), his HCV viral load was 81 286 IU/mL and the S282T mutation was no longer detectable. He initiated sofosbuvir plus ledipasvir treatment 50 weeks after relapse.
Virologic Response
Each of the 14 patients treated with sofosbuvir plus ledipasvir had HCV RNA levels below the lower limit of quantification by 4 weeks (Roche Cobas TaqMan HCV Assay, version 2.0), which was maintained through the end of treatment (12 weeks). All patients achieved SVR 12 weeks after completion of treatment.
Changes in Hemoglobin Levels
No significant change in hemoglobin levels during sofosbuvir plus ledipasvir treatment was seen, in contrast to the decrease seen with sofosbuvir plus ribavirin. The mean hemoglobin level change was 0.07 g/L versus Ϫ11.70 g/L at 4 weeks (P ϭ 0.01), Ϫ0.5 g/L versus Ϫ12.6 g/L at 8 weeks (P ϭ 0.01), and Ϫ3.1 g/L versus Ϫ12.1 g/L at 12 weeks (P ϭ 0.06) with sofosbuvir plus ledipasvir and sofosbuvir plus ribavirin, respectively. No participant had a decrease in hemoglobin level of 15.0 g/L or greater with sofosbuvir plus ledipasvir compared with 8 of 14 (57%) with sofosbuvir plus ribavirin.
Changes in Renal Function
Renal variables did not change significantly over the course of treatment, although a single participant with grade 2 renal insufficiency at baseline (estimated glomerular filtration rate, 54 mL/min/1.73 m 2 ) developed a grade 3 event. After 6 weeks of receiving study medications, he had received amoxicillin in the context of a dental procedure and continued preenrollment medications (benazepril, telmisartan, and simvastatin). In this context, his estimated glomerular filtration rate decreased to 29 mL/min/ 1.73 m 2 (grade 3 toxicity); however, it improved (grade 2) within 1 week of withdrawing amoxicillin, returned to baseline within 3 weeks, and remained stable thereafter. He received study drugs without interruption. Discontinuation of sofosbuvir plus ledipasvir due to adverse events, n (%) 0
Serious adverse event, n (%) 0
Adverse event, n (%) Loose stool 1 (7) Constipation 1 (7) Headache 1 (7) Myalgia 2 (14) Nasal congestion 1 (7) Pruritic rash 1 ALT ϭ alanine aminotransferase; AST ϭ asparate aminotransferase; SGOT ϭ serum glutamic oxaloacetic transaminase; SGPT ϭ serum glutamic pyruvic transaminase. BMI ϭ body mass index; GT-1 ϭ genotype 1; HCV ϭ hepatitis C virus; IQR ϭ interquartile range. * Race was self-reported.
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Safety
All patients completed treatment, and no grade 4 adverse events or laboratory abnormalities occurred. The most common adverse events were myalgia and hypophosphatemia, and most adverse events were mild ( Table 2) . Four grade 3 events occurred (increased creatinine levels described above [n ϭ 1], hypercholesterolemia [n ϭ 1], and hypophosphatemia [n ϭ 2]).
DISCUSSION
In this study, we demonstrate that patients with HCV GT-1 who have viral relapse after sofosbuvir plus ribavirin therapy can be successfully re-treated with sofosbuvir plus ledipasvir. Seven (50%) of the patients in this study had advanced liver disease, which has been shown to be associated with relapse after sofosbuvir plus ribavirin therapy (8, 10, 11) . In addition to having a high prevalence of traditionally poor predictive factors for successful IFN-based treatment outcome, this cohort included 1 patient with a detectable S282T mutation after sofosbuvir plus ribavirin treatment (8, 10, 11) .
To our knowledge, this is the first trial to evaluate the use of alternative IFN-free DAA therapy for patients who have relapse after receiving a DAA-only regimen. Presence of the S282T mutation confers resistance to sofosbuvir in vitro (18, 19) . In clinical trials to date, most patients in which sofosbuvir-based treatment was unsuccessful had a relapse of HCV after completing treatment rather than return of the virus during treatment, and only rarely have S282T mutations been detectable, consistent with the results reported here (1 of 14 with detectable S282T mutations). Although rarely detected in vivo, it remains possible that S282T mutations are causally associated with relapse, and inability to commonly detect the mutation may relate to reduced viral fitness with replacement by wild-type virus as the predominant species by the time relapse is detected at follow-up (20 -22) . In this regard, the ideal management strategy for patients who have viral relapse after receiving sofosbuvir-containing regimens is unclear. Few published studies on the re-treatment of patients with HCV variants resistant to DAAs are available, and thus far, all retreatment strategies included the use of pegylated IFN and ribavirin. The favorable treatment outcome in the patient with the S282T mutation suggests that previous detection of S282T does not necessarily preclude future successful use of a sofosbuvir-containing regimen.
The major limitations of this study are the small sample size and the lack of in-depth viral sequencing, which could have identified more patients with S282T mutations after sofosbuvir plus ribavirin-associated relapse. We also did not assess NS5A baseline variants, and naturally occurring resistance-associated variants conferring decreased ledipasvir susceptibility have been reported in 4% to 12% of persons with HCV at baseline (15, (23) (24) (25) . Whether the presence of these resistance-associated variants will affect treatment outcome in the setting of previous relapse with sofosbuvir requires testing in larger studies. The retreatment occurred 1 year after initial relapse, and whether re-treatment earlier would have resulted in similar SVR rates is unknown.
In conclusion, our study suggests that patients who have viral relapse after sofosbuvir plus ribavirin can be successfully re-treated with sofosbuvir plus ledipsavir for 12 weeks. The low incidence of adverse events, low pill burden, shorter treatment duration, and high efficacy demonstrated in this group and other populations make this drug combination attractive in a real-world setting. This new paradigm in the management of patients with HCV should be further tested in larger clinical trials for those who have relapse after sofosbuvir therapy with all HCV genotypes, including patients with comorbid conditions, such as transplantation and cirrhosis. Note: Drs. Osinusi and Kottilil had full access to all data in the study and take responsibility for the integrity and accuracy of the data analysis. Drs. Kottilil, Osinusi, and Masur and Ms. Marti had unrestricted access to the data and wrote the manuscript. Subsequent drafts of the manuscript reflect comments from all coauthors. All authors reviewed and approved the final manuscript.
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